Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solvay To Submit Audits To FDA Shortly In Effort To Be Removed From AIP List

Executive Summary

Solvay has indicated that the independent audits analyzing stability data generated by its manufacturing facilities will be submitted shortly to FDA as a step in being removed from the agency's application integrity policy list.

You may also be interested in...



Solvay Cleared From FDA Application Integrity Policy; Luvox Decision Pending

Solvay has been cleared from FDA's Application Integrity Policy list as of April 9

Solvay Cleared From FDA Application Integrity Policy; Luvox Decision Pending

Solvay has been cleared from FDA's Application Integrity Policy list as of April 9

Solvay Rowasa Supply Problems Get Help From Axcan Shipments To U.S.

Canadian firm Axcan has begun supplying 5-aminosalicylic acid suppositories to U.S. patients who have been unable to obtain Solvay's 5-ASA rectal suppository Rowasa.

Related Content

UsernamePublicRestriction

Register

PS036325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel